AstraZeneca mulls spinning off China activities: FT

Credit: Unsplash/CC0 Public Domain

Anglo-Swedish drugmaker AstraZeneca could spin off its Chinese division and list it in Hong Kong to minimize China-related risks, the Financial Times reported on Monday.

The company started discussions several months ago, the business daily said citing people familiar with the talks.

AstraZeneca declined to comment.

According to the FT, the drugmaker was seeking to diminish the risk of any potential Chinese crackdown on foreign companies.

AstraZeneca mulls spinning off China activities: FT

Taking a leave of absence can harm medical students' match prospects, finds study

In the nation's M.D.-Ph.D. programs, the socioeconomic gap widens

Police transport may influence restraint use in the emergency department

New tool can assess the climate of equity and inclusion in medical schools

Study: Why nurses are too often missing in health care leadership with major barriers to career advancement

The top Medical Xpress articles of 2023

Studying medicine, Nazism, and the Holocaust crucial to strengthening medical education and ethics, says new work

Study suggests two copies of APOE4 gene behind up to 20% of Alzheimer's cases

Researchers show genetic variant common among Black Americans contributes to large cardiovascular disease burden

First person to receive a genetically modified pig kidney transplant dies nearly 2 months later

New vaccine could protect against coronaviruses that haven't even emerged yet

Study links organization of neurotypical brains to genes involved in autism and schizophrenia

Study traces an infectious language epidemic

Visual experiences unique to early infancy provide building blocks of human vision, study finds

Study points to personalized treatment opportunities for glioblastoma

Research team introduces new tool to boost battle against childhood undernutrition

How herpes hijacks a ride into cells

How the brain is flexible enough for a complex world, without being thrown into chaos